Chiltern International Limited (Chiltern), a global contract research organization (CRO), announced a succession of Chief Executive Officer, with Glenn Kerkhof stepping down and Dr Jim Esinhart appointed.
After 6 years in the post Glenn Kerkhof will step down as Chief Executive Officer with effect from October 31. Glenn will join Chiltern’s owner Czura Thornton as a Partner and will join Chiltern’s Board of Directors. Glenn will relocate to his native Australia and will lead Czura Thornton’s growth in the Asia Pacific region.
Chiltern also announced the appointment of Jim Esinhart, PhD, as Chiltern’s new CEO with effect from November 1. Jim is currently Chiltern’s Senior Executive Vice President, Global Scientific Services and has served with the Company for 6 years. Jim has more than 24 years of industry experience and brings an outstanding track record of scientific excellence, operating performance and service delivery.
Mr. Kerkhof said: “I am delighted to have played my part in the development of Chiltern as a leading mid-tier CRO. Chiltern now employs more than 1,400 people in 34 countries, is financially very strong and is poised for substantial growth. I am also delighted to see the CEO position transition to a valued and trusted colleague in Jim Esinhart, who I know will bring a tremendous amount to the role. And I very much look forward to contributing to Chiltern’s future as a member of the Board based in the Asia Pacific region.”
Dr Esinhart added: “On behalf of the whole Chiltern team I would like to pay tribute to Glenn, who has been a fantastic leader of our Company. I am thrilled to have the opportunity to succeed him as Chiltern’s CEO and to continue our mission to deliver expert, high quality and comprehensive clinical development services to our clients around the world. I am excited by the momentum we have at Chiltern, by the strength of our team, the depth of our client partnerships and by the development opportunities we see.”
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Patient Engagement Platform Checklist
November 22nd 2024Modern clinical trials are more complex than ever, and one significant reason is the increased focus on patient engagement. Incorporating a patient engagement platform into your clinical trial enhances the patient experience and can lead to more successful trials with stronger, more reliable outcomes. We put together this helpful checklist of key features to look out for when choosing a platform for your study.